Back to News
Market Impact: 0.2
CMS's Hemp CBD Program Has A Physician Problem
Source: Newswire
Healthcare & BiotechRegulation & Legislation
Vantage Hemp's Chief Medical Officer called for standardized, reproducible cannabinoid products and controlled clinical trials to support broader healthcare adoption. The comments coincide with CMS extending its cannabinoid initiative through the 10-year LEAD Medicare model, signaling a longer-term policy and evidence-development focus rather than an immediate financial catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Christine Lagarde: Interview with Ouest-France
- Mortgage lending standards are so tight that homebuyers must have ‘pristine’ credit histories, study says, as sales head for 31-year low
- OpenAI IPO will not happen in 2026 amid AI safety fears, Sam Altman says
- The ghost cartel — your pricing algorithm may have stopped competing without your knowledge
- A flawed system and one man’s hubris cost Meta shareholders $17 billion
- After a decade of failed bills and three years of resignations, Washington finally discovers it cares about AI safety